Predictive factors of revision endoscopic sinus surgery

Aguiar, Cristina; Valente, Pedro; Medeiros, Nuno; Ribeiro, Leandro; Lima, Nuno Barros; Oliveira, Pedro

doi:10.1007/s00405-023-07856-7

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A certain bias is inherent to the design because patients having already failed surgery currently improving with Dupilumab might be more likely to answer the questionnaire in this specific study setting. However, the lived experience of recurrence is common in CRSwNP and this study displays a representative patient cohort seen in tertiary health care centres [23][24][25]. 100 patients received the questionnaire and the return rate of completed questionnaires was 88%, indicating a fairly comprehensive sample among all the patients that were approached.…”

Section: Discussionmentioning

confidence: 99%

Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps

Gangl,

Liu,

Bartosik

et al. 2024

JPM

View full text Add to dashboard Cite

(1) Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) has a high rate of recurrence in patients, despite therapy with local corticosteroids and functional endoscopic sinus surgery. Dupilumab, a recombinant monoclonal human IgG4 antibody directed against the IL-4 receptor α that inhibits both IL-4 and IL-13 signal transduction, is available for symptomatic therapy. Patient preference between repeated surgery and injection therapy with Dupilumab is not known. (2) Methods: Patients who had experienced at least one surgical intervention for nasal polyps and were treated with Dupilumab for at least 3 months completed a retrospective patient questionnaire. (3) Results: In a cohort of 75 previously operated CRSwNP patients, 91.5% preferred therapy with Dupilumab to repeated surgery for nasal polyps. Preference for Dupilumab in the subgroups of patients with concomitant Non-steroidal Anti-inflammatory Drugs Exacerbated Respiratory Disease (N-ERD) (n = 32), patients with concomitant asthma (n = 25), and patients without concomitant disease (n = 18) was 100%, 96%, and 72%, respectively. (4) Conclusions: Patient preference for Dupilumab over repeat surgery is strongest in previously operated CRSwNP patients with concomitant asthma or N-ERD, but remains very high in patients without concomitant disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-Life Study of Patient Preference for Dupilumab or Revision Surgery for Recurrent Chronic Rhinosinusitis with Nasal Polyps

Gangl,

Liu,

Bartosik

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

“…This finding is in accordance with other authors, who describe worse preoperative severity of nasal polyposis as a risk factor for recurrence. 2,25 Shifting attention from clinically available predictors to more pathological-oriented ones, one of the most-mentioned prediction factors for recurrence is tissue eosinophilia. A systematic review and meta-analysis 26 on the matter suggest that high-tissue eosinophilia is associated with difficult-to-treat CRS.…”

Section: Discussionmentioning

confidence: 99%

“…This finding is in accordance with other authors, who describe worse preoperative severity of nasal polyposis as a risk factor for recurrence. 2,25…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-125b Is a Potential Predictor of Surgical Outcomes in Chronic Rhinosinusitis with Nasal Polyps

Gata,

Leucuta,

Budisan

et al. 2024

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background Despite advances in surgical techniques, recurrence rates after endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP) remain high and difficult to predict. Objective This study aimed to evaluate the potential role of microRNA 125b (miR-125b) in predicting disease evolution following ESS. Methods We conducted a prospective study including patients undergoing first ESS for CRSwNP in our department between January 2020 and November 2021. We determined miR-125b levels from nasal polyps and pursued a standardized follow-up for at least 18 months for each patient. Results A total of 86 patients were included in the study. Higher postoperative endoscopy scores were associated with more severe disease at presentation on computed tomography scan, presence of concomitant asthma, and higher values of miR-125b. Even after multivariate repeated measures analysis and adjustments for confounders, miR-125b remained statistically significant. Moreover, miR-125 was the most important factor in predicting disease evolution at 18 months. Conclusion A clear, robust relation between nasal polyp control evaluated through objective measures and miR-125b values was observed. This finding indicates the potential role of miR-125b in predicting the course of the disease following ESS.

show abstract